Liquid biopsy (LB) is a growing tool that investigates molecular markers in body fluids (Blood, urine, saliva...etc.) to provide knowledge about tumor behavior, genetics and response to therapy. Liquid biopsy approaches include circulating tumor cells (CTC) and cell-free tumor products, such as circulating tumor DNA, microRNAs (miRNAs), long non-coding RNAs (lncRNA). LB has reported significant impact in detecting cancer at an early stage, observing tumor progression and recurrence, and predicting patient response to therapy. Several studies have demonstrated its clinical utility in many types of solid tumors as breast cancer, ovarian cancer, glioblastoma. Though, there are limitations to LB still to be reported, comprising of the lack of standardized assays and the necessity for further validation, its applications in managements is of a great era of research since it can provide an approach of promising non-invasive tool for cancer management.

Menha Swellam has completed her PhD 1999, she is professor since 2010, affiliated as a head of High Throughput Molecular & Genetic Technology Lab - Center of Excellence for Advanced Sciences, Biochemistry Department, Biotechnology Research Institute, National Research Centre. Has over one thousand citations, h-index 22, and over 60 publications. Served as visiting professor in Makerere University, Kampla – Uganda, an editorial board member of many reputed journals, revised many international projects and principle investigator for many projects.